Related Experiment Videos
The clinical pharmacology of loop diuretics in the pediatric patient
1Department of Clinical Pharmacy, Crippled Children's Foundation Research Center, University of Tennessee, Memphis, 38163, USA.
Insights
Loop diuretics like furosemide and bumetanide are common in children. Dosing must be carefully adjusted due to immature elimination, preventing toxicity and tolerance.
Area of Science:
- Pediatric Pharmacology
- Nephrology
- Clinical Therapeutics
Background:
- Loop diuretics (furosemide, bumetanide) are essential for managing fluid overload in pediatric patients.
- Infants exhibit distinct pharmacokinetics, including reduced clearance and prolonged half-life, increasing toxicity risk if dosing is not individualized.
- Limited data exist on the maturation of loop diuretic elimination in older children and adolescents.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, and pharmacodynamics of furosemide and bumetanide in pediatric populations.
- To highlight the importance of age-appropriate dosing to prevent accumulation and toxicity.
- To discuss strategies for managing diuretic tolerance and resistance in children.
Main Methods:
- Review of existing literature on loop diuretic use in pediatric patients.
- Analysis of pharmacokinetic and pharmacodynamic data specific to neonates, infants, children, and adolescents.
- Synthesis of clinical challenges and therapeutic approaches.
Main Results:
- Pediatric patients, especially infants, have significantly different drug elimination compared to adults, necessitating adjusted dosing intervals.
- A maximally effective diuretic dose likely exists, beyond which toxicity risk increases without additional benefit.
- Diuretic tolerance and resistance are common issues requiring specific management strategies.
Conclusions:
- Optimizing loop diuretic therapy in children requires a thorough understanding of their unique pharmacokinetic and pharmacodynamic profiles.
- Individualized dosing regimens are crucial to ensure efficacy while minimizing the risk of adverse events.
- Further research into the maturation of diuretic elimination pathways is needed to refine pediatric dosing guidelines.
Abstract:
The loop diuretics furosemide and bumetanide are frequently employed in the pediatric population for the management of fluid overload in both acute and chronic disease states. They act mainly by inhibiting sodium reabsorption in the nephron at the thick ascending limb of Henle's loop. Important pharmacokinetic differences between adults and infants include a reduced clearance and prolonged half-life, that may cause accumulation of these agents to potentially toxic levels if dosing intervals are not adjusted. Unfortunately, little is known about the time required for maturation of loop diuretic elimination in older infants, children, and adolescents. Similar to adults, limited pharmacodynamic evidence in neonates suggests that a maximally efficient diuretic dose exists. Increasing the diuretic dose beyond this maximum does not offer further benefit, but may increase the risk of toxicity. Common problems encountered in the pediatric patient as well as in adults are loop diuretic tolerance and resistance. Loop diuretic dosing strategies aimed at overcoming these phenomena include administration by continuous infusion, coadministration with albumin, and coadministration with metolazone or thiazides. This article reviews the pharmacology, pharmacokinetics, and pharmacodynamics of furosemide and bumetanide in pediatric patients. A better understanding of the clinical pharmacology of the loop diuretics should aid clinicians in the development of dosing regimens aimed at producing adequate diuresis without promoting excessive diuretic tolerance.